Multimodal imaging to distinguish microvascular and morphological changes in retinal vein occlusion after intravitreal ranibizumab with or without triamcinolone acetonide injection.
Humans
Retinal Vein Occlusion
/ drug therapy
Retrospective Studies
Intravitreal Injections
Male
Triamcinolone Acetonide
/ administration & dosage
Female
Ranibizumab
/ administration & dosage
Angiogenesis Inhibitors
/ therapeutic use
Tomography, Optical Coherence
/ methods
Middle Aged
Visual Acuity
Fluorescein Angiography
/ methods
Glucocorticoids
/ therapeutic use
Aged
Multimodal Imaging
Retinal Vessels
/ pathology
Drug Therapy, Combination
Intravitreal ranibizumab injection
Intravitreal triamcinolone acetonide injection
Microvascular and morphological changes
Multimodal imaging
Optical coherence tomography angiography
Retinal vein occlusion
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
20
04
2024
accepted:
06
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
The study was designed to investigate microvascular and morphological changes in retinal vein occlusion (RVO) using multimodal imaging after intravitreal ranibizumab (IVR) with or without triamcinolone acetonide (IVTA) injections. This was a retrospective and observational study. Fifty patients (52 eyes) diagnosed with RVO were enrolled. Best corrected visual acuity (BCVA), ophthalmoscopy, fundus fluorescein angiography (FFA), spectral domain optical coherence tomography (SDOCT), and optical coherence tomography angiography (OCTA) were employed sequentially both before treatment and at the last visit after treatment. The mean logMAR VAs in BRVO eyes decreased significantly after treatment (P = 0.029). OCTA showed there was a significant difference in foveal avascular zone (FAZ) in BRVO eyes (P = 0.024), superificial foveal vessel density in both CRVO (P = 0.0004) and BRVO eyes (P = 0.02155). OCT showed the foveal thickness had significant differences after treatment in both CRVO (P < 0.0001) and BRVO eyes (P = 0.0001). BCVA was associated most commonly with ellipsoid zone integrity (P = 0.022). The BCVA in eyes treated with IVR and IVTA was significantly decreased compared with IVR only in BRVO group (P = 0.021). However, the combination of IVR + IVTA significantly improved intraocular pressure (IOP) compared with IVR only in BRVO group (P = 0.037). Both IVR and IVR + IVTA can significantly improve the central vision, macular structure, and functions in BRVO group. Simultaneous IVR with IVTA can significantly increase BCVA compared with IVR only in BRVO group.
Sections du résumé
BACKGROUND
BACKGROUND
The study was designed to investigate microvascular and morphological changes in retinal vein occlusion (RVO) using multimodal imaging after intravitreal ranibizumab (IVR) with or without triamcinolone acetonide (IVTA) injections.
METHODS
METHODS
This was a retrospective and observational study. Fifty patients (52 eyes) diagnosed with RVO were enrolled. Best corrected visual acuity (BCVA), ophthalmoscopy, fundus fluorescein angiography (FFA), spectral domain optical coherence tomography (SDOCT), and optical coherence tomography angiography (OCTA) were employed sequentially both before treatment and at the last visit after treatment.
RESULTS
RESULTS
The mean logMAR VAs in BRVO eyes decreased significantly after treatment (P = 0.029). OCTA showed there was a significant difference in foveal avascular zone (FAZ) in BRVO eyes (P = 0.024), superificial foveal vessel density in both CRVO (P = 0.0004) and BRVO eyes (P = 0.02155). OCT showed the foveal thickness had significant differences after treatment in both CRVO (P < 0.0001) and BRVO eyes (P = 0.0001). BCVA was associated most commonly with ellipsoid zone integrity (P = 0.022). The BCVA in eyes treated with IVR and IVTA was significantly decreased compared with IVR only in BRVO group (P = 0.021). However, the combination of IVR + IVTA significantly improved intraocular pressure (IOP) compared with IVR only in BRVO group (P = 0.037).
CONCLUSION
CONCLUSIONS
Both IVR and IVR + IVTA can significantly improve the central vision, macular structure, and functions in BRVO group. Simultaneous IVR with IVTA can significantly increase BCVA compared with IVR only in BRVO group.
Identifiants
pubmed: 39164640
doi: 10.1186/s12886-024-03619-y
pii: 10.1186/s12886-024-03619-y
doi:
Substances chimiques
Triamcinolone Acetonide
F446C597KA
Ranibizumab
ZL1R02VT79
Angiogenesis Inhibitors
0
Glucocorticoids
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
354Subventions
Organisme : Natural Science Foundation of Hunan Province
ID : No.2023JJ30003
Organisme : Natural Science Foundation of Hunan Province
ID : No.2023JJ30748
Organisme : Scientific Research Project of Hunan Provincial Health Commission
ID : No.C202307027337
Organisme : Scientific Research Project of Hunan Provincial Health Commission
ID : No.D202307028349
Organisme : Natural Science Foundation of Changsha
ID : No. kq2208494
Organisme : Science and Technology Program of Changsha
ID : No.kh2302036
Informations de copyright
© 2024. The Author(s).
Références
Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol. 2018;63(6):816–50.
doi: 10.1016/j.survophthal.2018.04.005
pubmed: 29705175
Noma H, Mimura T, Eguchi S. Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol. 2013;131(2):160–5.
doi: 10.1001/2013.jamaophthalmol.228
pubmed: 23411880
Rezar-Dreindl S, Eibenberger K, Pollreisz A, Bühl W, Georgopoulos M, Krall C, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. Acta Ophthalmol. 2017;95(2):e119–27.
doi: 10.1111/aos.13152
pubmed: 27417275
Zhang S, An N, Ha W, Zhang S, Hu X, Ma A, et al. Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion. J Int Med Res. 2016;44(3):685–97.
doi: 10.1177/0300060515617386
pubmed: 26936966
pmcid: 5536696
Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol Vis Sci. 1977;16(1):69–73.
pubmed: 319076
Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103(5):708–11.
doi: 10.1001/archopht.1985.01050050100026
pubmed: 2581536
Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol. 2001;425(2):109–16.
doi: 10.1016/S0014-2999(01)01192-X
pubmed: 11502275
Sze PY, Iqbal Z. Glucocorticoid action on depolarization-dependent calcium influx in brain synaptosomes. Neuroendocrinology. 1994;59(5):457–65.
doi: 10.1159/000126692
pubmed: 8022521
Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E. Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110(8):1155–9.
doi: 10.1001/archopht.1992.01080200135041
pubmed: 1497531
Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 2002;43(9):3125–30.
pubmed: 12202538
Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, et al. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Surv Ophthalmol. 2013;58(4):291–310.
doi: 10.1016/j.survophthal.2012.08.003
pubmed: 23768920
Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf. 2012;11(2):331–40.
doi: 10.1517/14740338.2012.635141
pubmed: 22066820
Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101(2):190–5.
doi: 10.1016/0002-9394(86)90593-3
pubmed: 3753824
Terasaki H, Ogura Y, Kitano S, Sakamoto T, Murata T, Hirakata A, et al. Management of diabetic macular edema in Japan: a review and expert opinion. Jpn J Ophthalmol. 2018;62(1):1–23.
doi: 10.1007/s10384-017-0537-6
pubmed: 29210010
Fan C, Wang Y, Ji Q, Zhao B, Xie J. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion. Curr Eye Res. 2014;39(9):938–43.
doi: 10.3109/02713683.2014.885533
pubmed: 24635755
Hirano Y, Suzuki N, Tomiyasu T, Kurobe R, Yasuda Y, Esaki Y et al. Multimodal Imaging of Microvascular Abnormalities in retinal vein occlusion. J Clin Med. 2021, 10(3).
Cicinelli MV, Sadiq SA, Mishra S, Jampol LM, Mirza RG. Multimodal Imaging Characterization of Arteriolosclerotic Plaques in retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2021;52(12):650–7.
doi: 10.3928/23258160-20211118-01
pubmed: 34908486
Remolí Sargues L, Montero Hernández J, Navarro Palop C, Monferrer Adsuara C, Castro Navarro V, Cervera Taulet E. Multimodal imaging of two cases of retinal vein occlusion secondary to Waldenstrom macroglobulinemia. Eur J Ophthalmol. 2022;32(3):Np50–5.
doi: 10.1177/1120672121991389
pubmed: 34154441
Sun Z, Zhou H, Lin B, Jiao X, Luo Y, Zhang F, et al. Efficacy and Safety of Intravitreal Conbercept Injections in Macular Edema Secondary to retinal vein occlusion. Retina. 2017;37(9):1723–30.
doi: 10.1097/IAE.0000000000001404
pubmed: 27893623
pmcid: 5598918
Dikmetas O, Kuehlewein L, Gelisken F. Rebound Phenomenon after Intravitreal Injection of Triamcinolone Acetonide for Macular Edema. Ophthalmologica. 2020;243(6):420–5.
doi: 10.1159/000507712
pubmed: 32252055
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101–14.
doi: 10.1001/archophthalmol.2009.234
pubmed: 19752419
pmcid: 2872173
Suzuki N, Hirano Y, Tomiyasu T, Esaki Y, Uemura A, Yasukawa T, et al. Retinal hemodynamics seen on Optical Coherence Tomography Angiography before and after treatment of retinal vein occlusion. Invest Ophthalmol Vis Sci. 2016;57(13):5681–7.
doi: 10.1167/iovs-16-20648
pubmed: 27784073
Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795–802.
doi: 10.1016/j.ophtha.2012.09.032
pubmed: 23260261
Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429–41.
doi: 10.1016/S0002-9394(14)70001-7
pubmed: 8154523
Shimura M, Yasuda K. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. Br J Ophthalmol. 2010;94(3):381–3.
doi: 10.1136/bjo.2009.160986
pubmed: 20215378
Huang ZL, Lin KH, Lee YC, Sheu MM, Tsai RK. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome. Ophthalmologica. 2010;224(2):86–9.
doi: 10.1159/000235726
pubmed: 19707032
Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS, et al. Changes in Retinal Nonperfusion Associated with suppression of vascular endothelial growth factor in retinal vein occlusion. Ophthalmology. 2016;123(3):625–e341.
doi: 10.1016/j.ophtha.2015.10.030
pubmed: 26712560
Mané V, Dupas B, Gaudric A, Bonnin S, Pedinielli A, Bousquet E, et al. Correlation between Cystoid spaces in Chronic Diabetic Macular Edema and Capillary Nonperfusion detected by Optical Coherence Tomography Angiography. Retina. 2016;36(Suppl 1):S102–10.
doi: 10.1097/IAE.0000000000001289
pubmed: 28005668
Winegarner A, Wakabayashi T, Fukushima Y, Sato T, Hara-Ueno C, Busch C, et al. Changes in Retinal Microvasculature and Visual Acuity after Antivascular endothelial growth factor therapy in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2018;59(7):2708–16.
doi: 10.1167/iovs.17-23437
pubmed: 29860457
Sabet-Peyman EJ, Heussen FM, Thorne JE, Casparis H, Patel SJ, Do DV. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging. 2009;40(3):316–8.
doi: 10.3928/15428877-20090430-17
pubmed: 19485300
Mansour AM, Bynoe LA, Welch JC, Pesavento R, Mahendradas P, Ziemssen F, et al. Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol. 2010;88(7):730–5.
doi: 10.1111/j.1755-3768.2009.01535.x
pubmed: 20039854
Chatziralli I, Dimitriou E, Lambadiari V, Kazantzis D, Kapsis P, Theodossiadis G et al. The impact of Laboratory findings and Optical Coherence Tomography biomarkers on response to Intravitreal Anti-VEGF Treatment in patients with Diabetic Macular Edema. Semin Ophthalmol. 2022:1–8.
Ghashut R, Muraoka Y, Ooto S, Iida Y, Miwa Y, Suzuma K, et al. Evaluation of Macular Ischemia in eyes with central retinal vein occlusion: an Optical Coherence Tomography Angiography Study. Retina. 2018;38(8):1571–80.
doi: 10.1097/IAE.0000000000001749
pubmed: 28671896
Iacono P, Parodi MB, Scaramuzzi M, Bandello F. Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol. 2017;101(6):791–5.
doi: 10.1136/bjophthalmol-2016-308726
pubmed: 27625164
Sevgi DD, Yee PS, Srivastava SK, Le TK, Abraham JR, Reese J, et al. Longitudinal Ellipsoid Zone dynamics after Macular Hole Repair in the Discover Study. Structure-Function Assess Retina. 2021;41(5):915–20.
pubmed: 33887747
Tuifua TS, Abraham JR, Srivastava SK, Kaiser PK, Reese J, Ehlers JP. Longitudinal ellipsoid zone and Outer Retinal Integrity Dynamics after Epiretinal membrane surgery. Retina. 2022;42(2):265–73.
doi: 10.1097/IAE.0000000000003306
pubmed: 34561406
pmcid: 8776576